| Sauer, Martin |
| Recruiting | 2/3 | 1800 | Europe, Canada, RoW | VP16, Etoposide, TBI, Thiotepa, Thio, Treosulfan, Treo, Fludarabine, Flu, Busulfan, Bu, ATG Thymoglobulin, ATG Thymo, Cyclophosphamide, Cy, Grafalon, Anti-human T-lymphocyte immunoglobulin | St. Anna Kinderkrebsforschung, ALL SCTped Forum, European Society for Blood and Marrow Transplantation, ALL-BFM Study Group, Assistance Publique - Hôpitaux de Paris, Dutch Childhood Oncology Group, Swiss Pediatric Oncology Group, Australian & New Zealand Children's Haematology/Oncology Group | Acute Lymphoblastic Leukaemia | 06/25 | 04/30 | | |
| Recruiting | 2 | 142 | Europe | ARTICE | Artcline GmbH, Zentrum für Klinische Studien Jena, CRO Kottmann | Sepsis, Severe | 12/24 | 05/25 | | |
| Recruiting | 2 | 200 | Europe | Pentaglobin®/Standard of Care | RWTH Aachen University, Biotest | Peritonitis, Sepsis, Septic Shock | 09/27 | 03/28 | | |
NCT04277598: A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer |
|
|
| Completed | 1/2 | 159 | Europe, RoW | APO-2, Placebo | Aposcience AG, FGK Clinical Research GmbH | Diabetic Foot Ulcer (DFU) | 12/23 | 12/23 | | |
ReActIF- LTO, NCT06143137: Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up |
|
|
| Recruiting | N/A | 142 | Europe | | Artcline GmbH, ZKS Jena | Severe Sepsis | 12/29 | 02/30 | | |
| Heidel, Florian |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 03/24 | 03/24 | | |
| Recruiting | 2 | 30 | Europe | Fedratinib Oral Capsule [Inrebic], Nivolumab | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Prof. F. Heidel, MH Hannover, Celgene International II S.á.r.l. | Primary Myelofibrosis, Secondary Myelofibrosis | 12/25 | 06/26 | | |
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions |
|
|
| Recruiting | 2 | 213 | Europe | Luspatercept Injection, LUS | University of Leipzig, Celgene Corporation | Myelodysplastic Syndromes, Anemia | 07/26 | 07/27 | | |
| Recruiting | 1/2 | 199 | Europe, Canada, US | Ziftomenib | Kura Oncology, Inc. | Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | 09/24 | 09/25 | | |
| Recruiting | N/A | 552 | Europe, US, RoW | | Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net | Myeloproliferative Neoplasm, COVID | 02/22 | 08/22 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2) | | | | |
NCT03125707: German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm) |
|
|
| Recruiting | N/A | 2172 | Europe | Registry study | University of Ulm | BCR-ABL1-Negative Myeloid Neoplasms | 09/45 | 09/45 | | |
| Welte, Tobias |
| Completed | 3 | 140 | Europe | Anticoagulation Agents (Edoxaban and/or high dose LMWH), Low dose Low molecular weight heparin or Placebo | Universitätsklinikum Hamburg-Eppendorf | Covid19 | 09/22 | 01/23 | | |
| Recruiting | 3 | 390 | Europe, RoW | Trimodulin, BT588, Placebo (human albumin 1%) | Biotest | Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, COVID-19, Viral Pneumonia, Bacterial Pneumonia, Fungal Pneumonia | 08/25 | 08/25 | | |
| Recruiting | 3 | 526 | Europe, US, RoW | Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo | Dompé Farmaceutici S.p.A | Infectious Pneumonia, Severe COVID-19 | 09/24 | 10/24 | | |
ESsCAPE, NCT05722938: Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) |
|
|
| Recruiting | 3 | 590 | Europe, US, RoW | Trimodulin, BT588, Placebo (human albumin 1%) | Biotest | Community-acquired Pneumonia | 02/25 | 04/25 | | |
| Recruiting | 3 | 1700 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 09/25 | 09/25 | | |
|
NCT04575064: An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY |
|
|
| Active, not recruiting | 2/3 | 400 | Europe | Standard of Care (SoC), Remdesivir | Professor Dr. Bernd Mühlbauer, Dept. of Statistics and Medical Biometry, University of Bremen, INSERM (Institut national de la santé et de la recherche médicale), Paris, France, World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland | SARS-CoV-2 Infection, COVID-19, Moderate and Severe COVID-19 | 03/22 | 11/22 | | |
| Terminated | 2 | 16 | Europe | Adrecizumab (HAM 8101), Placebo, Saline | Universitätsklinikum Hamburg-Eppendorf | COVID-19 | 08/23 | 11/23 | | |
| Recruiting | N/A | 2050 | Europe | prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 04/24 | 04/24 | | |
TRIBE, NCT05652439: PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI) |
|
|
| Recruiting | N/A | 25000 | Europe | Observational retrospective data collection, No treatment given | Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 08/26 | 08/26 | | |
| Muller, Thomas |
NCT05357989: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
NCT01299168: Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation |
|
|
| Recruiting | N/A | 500 | Europe, Canada, US, RoW | | University of Alberta | Validation Study of Molecular Diagnostic System, Development of Reporting System for Molecular Diagnosis, Incorporate Molecular Diagnosis Into Diagnostic Standards | 12/24 | 06/25 | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx, Prospera, transplant patient blood sample, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Kidney Transplant Rejection | 12/24 | 12/25 | | |
